34 articles for LC Kuo
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Merck Research Laboratories
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.
Merck Research Laboratories
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
Merck Research Laboratories
Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
Merck Research Laboratories
An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
University of Pennsylvania
Design and synthesis of potent and selective macrocyclic thrombin inhibitors.
Merck Research Laboratories
Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.
Johnson & Johnson Pharmaceutical Research and Development
Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.
Johnson & Johnson Pharmaceutical Research and Development
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
Merck Research Laboratories
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
Merck Research Laboratories
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Merck Research Laboratories
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
Merck Research Laboratories
Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.
Merck Research Laboratories
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
Merck Research Laboratories
Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position.
Merck Research Laboratories
Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.
Merck Research Laboratories
Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.
Merck Research Laboratories
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
Merck Research Laboratories
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
Merck Research Laboratories
Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
Merck Research Laboratories
1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitors.
Pharmacor
Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
Merck Research Laboratories